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Background: While guidelines recommend a lower systolic blood pressure (SBP) goal in diabetic patients, the impact of stricter SBP control on 
atheroma progression in diabetics remains unknown.
Methods: Atheroma progression in 3479 patients with CAD was analyzed by intravascular ultrasound, and compared in diabetic patients (n=1129) 
stratified by on-treatment SBP level.
Results: Anti-hypertensive drugs were more frequently used in diabetic patients (ACE-I 65 v. 49%, p<0.001, ARB 25 v. 16%, p<0.001, calcium 
channel blocker 41 v. 37%, p=0.007) than non-diabetics. Despite this, diabetic patients had higher on-treatment SBP (131±13 v. 128±13mmHg, 
p<0.001) and less achieved SBP<120mmHg (20 v. 27%, p<0.001). Diabetic patients with a SBP <120mmHg were younger (56 v. 59 years, 
p<0.001), less likely to have a history of hypertension (79 v. 90%, p<0.001) and had lower baseline levels of SBP (115±13 v. 134±15 mmHg, 
p<0.001) and diastolic blood pressure (71±8 v. 77±15mmHg, p<0.001). While SBP<120mmHg was related to less change in percent atheroma 
volume, substantial atheroma progression was still observed. However, strict control of both SBP and LDL-C attenuated atheroma progression (Table).
Conclusions: Less diabetic patients achieve stricter SBP goal despite a greater use of anti-hypertensive drugs. While SBP control leads to less 
atheroma progression, the greatest impact is observed in patients with optimal multiple risk control. This underscores the intensive global risk 
control in diabetic patients.
 
